Kairos Pharma’s (KAPA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research report report published on Thursday,Benzinga reports. The brokerage currently has a $9.00 price objective on the stock.

KAPA has been the topic of a number of other research reports. Maxim Group began coverage on Kairos Pharma in a report on Thursday, March 27th. They issued a “buy” rating and a $4.00 target price on the stock. HC Wainwright initiated coverage on shares of Kairos Pharma in a report on Thursday, April 3rd. They issued a “buy” rating and a $12.00 price target on the stock.

Kairos Pharma Price Performance

Shares of Kairos Pharma stock opened at $0.96 on Thursday. The company has a 50-day moving average price of $1.09. Kairos Pharma has a one year low of $0.85 and a one year high of $4.00.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.